secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-08-06T11:23:01+00:00
Accession:  0001819790-26-000063
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus
--------------------------------------------------------------------------------

- XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.
- Net loss narrowed to $18.6M ($0.43 loss per share) from $20.3M ($0.48) in Q2 2025.
- Cash, cash equivalents and marketable securities $449.7M as of June 30, 2026.
- Announced agreement to acquire Alkeus Pharmaceuticals (Phase 3 Stargardt disease therapy) and $125M private placement.
- Appointed Neera Clase as Interim Chief Commercial Officer; pipeline milestones on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/0001819790-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/tars-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer